Josh Brown notices a "massive multi-year breakout" in biotech stocks (IBB +0.9%), with further...

|By:, SA News Editor

Josh Brown notices a "massive multi-year breakout" in biotech stocks (IBB +0.9%), with further gains likely as large pharmas continue to acquire the smaller firms so long as their own R&D departments are starving. "They have tons of cash and a burning desire to add pipeline - which makes almost every publicly-traded biotech a target for someone."